Edaravone is under clinical development by Treeway and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Edaravone’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 11 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Edaravone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Edaravone overview

Edaravone (TW-001) is under development for the treatment of amyotrophic lateral sclerosis and Alzheimer's Disease. The drug candidate is administered through oral route.The drug candidate is a neuroprotective agent. It targets free radicals.

Treeway overview

Treeway is a biotechnology company that develops drugs for the treatment of amyotrophic lateral sclerosis (ALS). The company’s clinical programs include TW001, an oral formulation of edaravone, which protects against neuronal apoptosis and oxidative stress. Its pre clinical program TW002, is an AAV5-GDNF gene therapy that offers an innovative administration modality for clinical use. Treeway‘s discovery research activities include project minE, motor neuron signalling, the immune system, and others. The company collaborates with research and clinical institutes for performing clinical trials in ALS. Treeway is headquartered in Tilburg, Noord-Brabant, the Netherlands.

Quick View Edaravone LOA Data

Report Segments
  • Innovator
Drug Name
  • Edaravone
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.